Non-coding DNA variants contribute to acute lymphoblastic leukemia (ALL) chemotherapy resistance. St. Jude Children's Research Hospital scientists have identified specific DNA variants in the ...
St. Jude Children’s Research Hospital scientists have identified specific DNA variants in the non-coding regions of the genome contributing to chemotherapy resistance in acute lymphoblastic leukemia ...
(L to R) Co-first author Jackson Mobley, PhD, corresponding author Daniel Savic, PhD, and co-first author Kashi Raj Bhattarai, PhD, all of the St. Jude Department of Pharmacy and Pharmaceutical ...
The non-coding genome, once dismissed as "junk DNA", is now recognized as a fundamental regulator of gene expression and a key player in understanding complex diseases. Following the landmark ...
Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA. The biotech focuses on trawling the 98% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback